VentriFlo Advances to Next Round for the MedTech Innovator Accelerator

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

March 22, 2019

VentriFlo has been identified as one of the top emerging MedTech startup companies in 2019 by the international MedTech Innovator competition. Out of more than 750 applicants, only the most promising 150 companies have been chosen to advance to the next level.

VentriFlo is honored to have been selected as one of the companies and will participate in the next-level qualifying event being held in Minneapolis, Minnesota, on March 27th, 2019.

Paul Grand, CEO of MedTech Innovator says in a recent article in LinkedIn’s Pulse, ”Our cohorts of Accelerator & Showcase companies undergo a rigorous narrowing process and are carefully selected from the best and brightest around the globe. These entrepreneurs are working tirelessly to address unmet medical needs, reduce the cost of care, ease the burden on physicians and care teams, and make life better for a significant number of people.”

As stated on MedTech Innovator’s website, “MedTech Innovator evaluates applicants along three different [axes] that help to identify the improved value to patient care and transformative potential: Value, Momentum, Execution.”

VentriFlo, a patented blood pump technology currently in development by Design Mentor, of Pelham, NH, recently won 2nd place in the NH Tech Alliance’s TechOut2018 Competition, and was also an award winner of the Children’s National Health System’s Pediatric Device Innovation Competition.

VentriFlo marks a revolutionary advancement over current blood pumps. Unlike the human heart, current blood pump technology uses continuous pressure to circulate blood. VentriFlo revolutionizes circulatory technology by delivering a life-like pulse to a patient during heart surgery and during post-surgical support when their own heart is unable to provide a native pulse.

With an experienced management and development team, and a world-renown list of Scientific Advisors, VentriFlo is well positioned to positively disrupt Heart-Lung medtech options. VentriFlo is poised to improve patient outcomes during surgery and in the years following, while decreasing the costs to hospitals, insurance companies and patients that are associated with longer hospital stays, readmissions and complications.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.